Anticholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease (Q24250271)

https://api.crossref.org/works/10.1002%2F14651858.CD003900

Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003900

Nebulised salbutamol with and without ipratropium bromide in acute airflow obstruction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003900

Severe exacerbations of COPD and asthma. Incremental benefit of adding ipratropium to usual therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003900

Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003900

Discovery & development of selective M3 antagonists for clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003900

The role of anticholinergic bronchodilators in adult asthma and chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003900

Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003900

Comparison of one versus two bronchodilators in ventilated COPD patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003900

Pharmacological treatment in acute exacerbations of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003900

A randomized controlled trial to assess the optimal dose and effect of nebulized albuterol in acute exacerbations of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003900

Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003900

Antimuscarinic effect of tiquizium bromide in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003900

Comparison of nebulized glycopyrrolate and metaproterenol in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003900

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003900

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003900

Bacterial infection in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003900

Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003900

Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003900

Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003900

7 January 2021

Chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003900

7 January 2021

Decreased duration of emergency department treatment of chronic obstructive pulmonary disease exacerbations with the addition of ipratropium bromide to β-agonist therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003900

7 January 2021

[Treatment of chronic bronchitis and chronic pulmonary obstructive disease in primary care]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003900

7 January 2021

A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003900

7 January 2021

Effects of 40 µg AND 400 µ of Ipratropium Bromide in Obstructive Lung Disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003900

7 January 2021

Effects of an anticholinergic bronchodilator on arterial blood gases of hypoxemic patients with chronic obstructive pulmonary disease. Comparison with a beta-adrenergic agent

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003900

7 January 2021

Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003900

7 January 2021

Is an anticholinergic agent superior to a beta 2-agonist in improving dyspnea and exercise limitation in COPD?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003900

7 January 2021

Routine nebulized ipratropium and albuterol together are better than either alone in COPD. The COMBIVENT Inhalation Solution Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003900

7 January 2021

A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003900

7 January 2021

10.1002/14651858.CD003900

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

4374032

OpenCitations bibliographic resource ID

4374032

1 reference